ARTICLE
Deference Principles: Tax Litigation’s Next Battleground
January 7, 2019
Read time: 10 min
Andrew Roberson and Timothy Shuman authored this bylined article on the development of deference principles and the implications for tax planning and litigation mattes going forward. “It is still too early to predict what will happen to the various deference doctrines, but it seems clear that courts are trending toward narrowly interpreting and applying these doctrines,” they wrote. “This is significant for TCJA regulations, which will undoubtedly be tested in the courts in the coming years.”
This article was originally published in Law360, January 7, 2019.
The Supreme Court’s recent decision to grant certiorari in the case of James L. Kisor v. Peter O’Rourke, Acting Secretary of Veteran Affairs, and revisit the question of whether an administrative agency’s interpretation of its own ambiguous regulations is entitled to deference, could have a cascading effect on deference principles in general. In the tax arena, this development has wide-ranging implications for tax planning and litigation matters going forward. Although taxpayers and tax professionals have wrestled with deference issues for years, this development takes on added importance given the major recent changes to the tax laws and Treasury’s tremendous effort to draft thousands of pages of regulations in response.
In our federal tax system, Congress enacts the tax laws. According to the Internal Revenue Manual:
It is the duty of the [Internal Revenue Service] to correctly apply the laws enacted by Congress; to determine the reasonable meaning of various Internal Revenue Code provisions in light of the Congressional purpose in enacting them; and to perform this work in a fair and impartial manner, with neither a government nor a taxpayer point of view.
This is accomplished through the issuance of published guidance — regulations, revenue rulings and revenue procedures, notices, and announcements — and private guidance — letter rulings, determination letters, technical advice memoranda, chief counsel advice, etc. — by the U.S. Department of the Treasury and the IRS. The IRS’ Office of Chief Counsel is tasked with enforcement of the Internal Revenue Code.
An agency’s ability to issue binding guidance is generally subject to various judicial doctrines, which can be grouped into three levels commonly referred to as Chevron, Skidmore and Auer deference.[1] A logical, but sometimes overlooked question is what is meant by the term “deference.” Importantly, “[d]eference does not mean acquiescence.”[2] However, depending on the type of administrative guidance, courts may treat an agency’s interpretation as binding so long as it is reasonable — even if another interpretation may also be reasonable, or even more reasonable. As explained below, whether to afford deference and the level of deference depends on the context of the agency’s interpretation and the medium in which it is made.
Chevron is the highest level of deference and traditionally has been applied to tax regulations. Eligibility for Chevron deference generally requires an ambiguous statute and a reasonable interpretation of the statute. If both requirements are met, a court will apply the agency’s interpretation, regardless of whether the court might believe that another interpretation is also reasonable — and possibly even more reasonable.
Skidmore deference has traditionally been applied to other forms of published guidance such as preambles to regulations, revenue rulings and procedures, notices and announcements. Eligibility for Skidmore deference depends on the level of persuasiveness, i.e., whether the IRS’ interpretation is thoroughly considered, well-reasoned and consistent with prior and subsequent IRS positions. Unlike Chevron deference, there are no set requirements to satisfy before a court will defer to the agency’s position; rather, the court will look at several factors and determine whether, under the circumstances, it should defer to the agency’s interpretation.
Finally, Auer deference is a unique standard that potentially applies to IRS interpretations of the IRS’s own ambiguous regulations. If certain conditions are met, the IRS’s interpretation will be afforded controlling deference based on the theory that the agency is the best party to interpret its own regulations. Similar to Chevron deference, so long as the necessary requirements are satisfied, a court will accept the agency’s interpretation even if it believes another interpretation is also reasonable.
Whether an administrative agency should be afforded deference, and the level of that deference, has been litigated in many contexts over the years. In recent years, the continuing vitality of deference doctrines has been questioned in both tax and non-tax cases. Guidance issued in the wake of the Tax Cuts and Jobs Act of 2017[3] and the change in membership of the U.S. Supreme Court have put these doctrines front and center for future tax disputes.
The Role of Deference Principles
The role of Auer deference in tax disputes was dormant for many years. However, the issue gained traction in recent years as a litigating tool as the IRS and the U.S. Department of Justice began to more regularly argue that their interpretations in legal briefs of ambiguous tax regulations should be afforded controlling deference. Trial and appellate courts have tended to be receptive to these arguments.
However, the Supreme Court in several cases over the past decade has slowly whittled away at the doctrine by providing limitations on how and when the doctrine can be used. For example, in addition to the requirement that the regulation be ambiguous: (1) the interpretation must not run counter to the agency’s intent at the time of the regulation’s promulgation, (2) the interpretation must reflect the agency’s fair and considered judgment on the issue and cannot be a convenient litigating position or a post hoc rationalization designed to defend past agency action against attack, (3) the regulation cannot merely parrot or restate the statutory language so that the agency, under the guise of interpreting the regulation, creates de facto a new regulation, (4) the interpretation must not be an unfair surprise or one that imposes a new liability for past actions taken in good faith reliance on prior agency announcements or positions and (5) in the tax context, deference may not be available unless the IRS’ interpretation is a matter of public record and is an interpretation that taxpayers are entitled to rely upon when planning their affairs.
Auer deference is also arguably at odds with two well-established canons of statutory construction.[4] The first — the rule of lenity — provides that penal statutes should be construed in favor of more lenient punishment. This rule has been applied in the civil tax context, both by the courts and by the IRS. The second — the strict construction canon — provides a general rule that ambiguities should be construed against the drafter. Courts have applied this rule in the context of ambiguous regulations.
Even Chevron deference has not been immune from attack in recent years, including by Congress and some judges. In 2017, the Separation of Powers Restoration Act[5] was introduced in the Senate to repeal Chevron deference, and presumably Skidmore and Auer deference, by amending the Administrative Procedure Act to require reviewing courts to determine “de novo all relevant questions of law, including the interpretation of constitutional and statutory provisions and rules.” A similar measure, named the Regulatory Accountability Act of 2017, was passed in the House of Representatives in 2017. And, in a recent concurring opinion in Pereira v. Sessions,[6] Associate Justice Anthony Kennedy cited concerns by Associate Justices Clarence Thomas and Neil Gorsuch regarding Chevron deference and observed that “it seems necessary and appropriate to reconsider, in an appropriate case, the premises that underlie Chevron and how courts have implemented that decision.”
The Tax Cuts and Jobs Act
The TCJA brought with it significant changes to the federal tax system and the need for Treasury and IRS guidance to assist taxpayers in navigating the new landscape. These changes included, but are not limited to, the new deduction for foreign-derived intangible income, or FDII, the new base erosion and anti-abuse tax, or BEAT, the new inclusion rule for global intangible low-taxed income, or GILTI, and amendments to IRC Section 163(j) limiting deductions for business interest expense. Treasury and the IRS have been working at a remarkable speed to issue published guidance in these areas, with various proposed and final regulations coming out since the TCJA was enacted. Some of the TCJA guidance has been welcomed by taxpayers; other guidance has been criticized as beyond the scope of laws enacted by Congress.
With significant tax issues and revenue at stake, the role of deference principles will be front and center in the coming years. This is particularly the case for Code sections enacted with a one-time effect and limited opportunity for taxpayer foresight and planning — e.g., Code Section 965 — and Code Sections for which regulations were or will be issued with retroactive effect to periods in which taxpayers undertook transactions in reliance on the language of the Code — e.g., Code Section 951A on GILTI.
Are Auer’s Days Numbered?
As noted above, the Supreme Court recently decided to revisit the question of whether any deference should be afforded to an agency’s interpretation of its own ambiguous regulations. Kisor v. O’Rourke,[7] will decide the sole question of “[w]hether the Court should overrule Auer and Seminole Rock” — the case upon which Auer is based. The decision to address this question is the culmination of Supreme Court justices’ questioning the doctrine’s continuing vitality for several years. Chief Justice John Roberts and Associate Justices Thomas and Samuel Alito have expressed doubts about the doctrine in the past, with Justice Thomas being particularly vocal in his belief that the doctrine violates the separation of powers.[8] With the recent additions of Associate Justices Gorsuch and Brett Kavanaugh, both of whom appear to be skeptical of expansive deference to agency interpretations, the stage is set for the overruling of Auer.
If Auer ends up on the chopping block, the next battleground may be Chevron deference. Justices Gorsuch and Kavanaugh have been critical of the doctrine in the past. And, recent majority, concurring and dissenting opinions reflect skepticism over the proper role of Chevron deference in deciding statutory interpretation questions. This approach appears to mirror the whittling away on Auer deference: Criticisms over the doctrine first surface in dissenting opinions and gradually make their way into concurring and then majority opinions.
Conclusion
Auer deference is particularly susceptible to challenge. Administrative agencies are often tasked with promulgating regulations that, in theory, should fill in gaps left by Congress and provide clear guidance. As the late Associate Justice Antonin Scalia and others have noted in the past, allowing an agency under the authority of Auer to later clarify its own ambiguous regulations, and to do so retroactively, arguably provides an incentive for the agency to draft ambiguous language that can later be interpreted in a manner that may not have been fully considered at the time of the original drafting. Chevron deference may also be subject to criticism, but at least it is understood that Congress cannot anticipate every issue that may arise and therefore expressly delegates authority to the agency generally — e.g., Code Section 7805 — or in the statute itself to fill in gaps. In contrast, Auer deference does not arise from a delegation of authority from Congress but rather constitutes a judicial doctrine that, in some cases, may result in a situation where the agency is no more capable of interpreting its own words than a court or a taxpayer. Additionally, Auer deference arguably runs counter to the well-established rule of lenity and the strict construction canon.
It is still too early to predict what will happen to the various deference doctrines, but even absent overruling of Auer or Chevron, it seems clear that courts are trending toward narrowly interpreting and applying these doctrines. This is significant for TCJA regulations, which will undoubtedly be tested in the courts in the coming years.
Call for Compliance: Cryptocurrency May Be Subject to US Tax
ARTICLE
Call for Compliance: Cryptocurrency May Be Subject to US Tax
January 4, 2019
Read time: 2 min
Laura Gavioli, Michael Louis, and Kevin Spencer authored this bylined article on taxing cryptocurrency and the questions surrounding reporting crypto holdings.
Eagle Mark Soars to Injunction Against Identical Hawk Logo
ARTICLE
Eagle Mark Soars to Injunction Against Identical Hawk Logo
January 4, 2019
Read time: 2 min
Sarah Hogarth authored this bylined article summarizing the US Court of Appeals for the Fifth Circuit’s decision to uphold a summary judgement saying a logo for a coalition infringed on an alliance’s trademark.

Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts
ARTICLE / CLIENT ALERT
Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts
January 4, 2019
Read time: 7 min
The US District Court for the District of Columbia recently held that the Centers for Medicare and Medicaid Services (CMS) exceeded its authority by reducing Medicare payment rates for 340B drugs, but, because of the budget-neutral nature of the cuts, the court left implementation details of its order temporarily unresolved to avoid disrupting administration of the Medicare Hospital Outpatient Prospective Payment System. It remains to be seen what remedies the court will ultimately order and whether CMS will appeal the decision.
On December 27, 2018, the US District Court for the District of Columbia held that the Centers for Medicare and Medicaid Services (CMS) exceeded its authority when it dramatically reduced Medicare payment rates for drugs purchased through the federal 340B drug discount program. The court acknowledged that the approximately 30 percentage point reduction in Medicare payment rates for 340B drugs was impermissible, but, because of the budget-neutral manner in which the payment cuts were implemented, the court left unresolved the question of how to effectuate the ruling, expressing concern about potentially wreaking “havoc” on the administration of the Medicare Hospital Outpatient Prospective Payment System (OPPS) if the court were to order CMS to make refunds to hospitals that were subject to the payment cuts during 2018. In the interest of avoiding such havoc, the court ordered the parties to submit briefs within 30 days suggesting how to remedy the issue.
In the meantime, many questions remain unanswered, such as: Will CMS appeal the ruling? When will the payment cuts be restored? Will CMS implement the expanded cuts to certain off-campus outpatient locations that were scheduled to take effect January 1, 2019? Will hospitals still be required to report claim modifiers related to the payment cuts?
Background on the 340B Payment Cuts
As discussed in an earlier OTS, as part of the Calendar Year (CY) 2018 updates to the OPPS (2018 Final Rule), CMS decreased Medicare Part B payments to hospitals for most separately payable drugs purchased through the 340B program and dispensed to hospital outpatients by almost 30 percent. Previously, CMS paid average sales price (ASP) plus 6 percent for these drugs when furnished to Medicare program beneficiaries, but under the 2018 Final Rule, effective January 1, 2018, CMS reduced reimbursement to ASP minus 22.5 percent for an almost 30 percentage point reduction in payment.
The 2018 Final Rule also required all hospitals participating in the 340B program paid under OPPS to report a modifier, regardless of whether the hospital was subject to the Medicare payment adjustment. Providers subject to the 340B-related payment adjustment are required to report modifier JG (drug or biological acquired with 340B Drug Pricing Program Discount) to identify if a drug was acquired under the 340B Program, while 340B hospitals that are exempt from the payment cut (rural SCHs, Children’s Hospitals and Cancer Hospitals) must report an informational modifier (TB).
CMS implemented the payment policy under the 2018 Final Rule in a budget-neutral manner, such that the Medicare program savings generated from the cut in drug payments are used to increase payments for all other services paid under OPPS, and are applicable to all hospitals. Accordingly, hospitals not subject to the payment reduction realized a substantial payment increase, which now is in question.
The American Hospital Association’s Lawsuit
Upon release of the 2018 Final Rule, the American Hospital Association (AHA) and America’s Essential Hospitals immediately sued CMS, claiming that the agency overstepped its statutory authority in reducing drug payments as outlined above. The original lawsuit was dismissed on jurisdictional grounds because the suit was filed before the 2018 Final Rule took effect and before any of the hospital plaintiffs had filed claims under the reduced reimbursement rate.
After losing an appeal in July 2018, the hospitals refiled the case in September 2018. The plaintiffs asked the court to require CMS to apply the 2017 OPPS drug reimbursement methodology—ASP plus 6 percent—to 340B drug payments made for the remainder of 2018, and pay the hospital plaintiffs, as well as all 340B program participants who are members of the association plaintiffs, the difference between the 340B drug payments received under the 2018 Final Rule and the higher payments that they would have received under the 2017 OPPS reimbursement methodology. The plaintiffs also asked the court to apply the 2017 OPPS reimbursement methodology in CY 2019 and subsequent years.
In its opinion, the court determined that “the [approximately 30 percent] reduction’s magnitude and its wide applicability inexorably lead to the conclusion that the Secretary fundamentally altered the statutory scheme established by Congress for determining [specified covered outpatient drug] reimbursement rates, thereby exceeding the Secretary’s authority to ‘adjust[]’ [specified covered outpatient drug] rates under § (t)(14)(A)(iii)(II).”
The court granted the plaintiffs’ motion, entitling them to equitable relief in the form of a permanent injunction against the payment cuts, but required both parties to provide a supplemental briefing on the appropriate remedy within 30 days. In the opinion, the Court noted that paying 340B hospitals at the 2017 rate, including retroactive payments, would likely be highly disruptive for CMS, since an important component of the payment policy its budget neutrality requirement. Therefore, increasing reimbursement rates for 2018 could require CMS to retrospectively reduce reimbursements elsewhere in the program for 2018—which the court expressed could create “havoc.”
Analysis and Key Takeaways
At this time, it is unclear what remedies the court will ultimately order and whether CMS will appeal the decision. Noting that neither party thoroughly addressed the question of remedies in their briefs, the court ordered supplemental briefings on the issue of remedies from both parties. The briefings are due to the court within 30 days of the December 27 ruling, after which the parties will each have two weeks to respond to one another’s briefs. The court will then make a ruling on the issue of remedies.
Affected hospitals should note the following key points:
- To date, CMS has made no public statements about the decision or its intentions to appeal or implement changes as a result.
- In the interim period before the court issues a ruling on the remedies, it appears that CMS will continue to pay for 340B drugs at the reduced rates under the 2018 Final Rule.
- The court confirmed in a footnote that its opinion did not address the expansion of the reduced payment rates under the 2019 Final Rule to include 340B drugs dispensed at off-campus outpatient locations subject to Section 603 of the Bipartisan Budget Act because the plaintiffs had not yet submitted a concrete claim for reimbursement under the 2019 Final Rule. The AHA has separately filed suit challenging the 2019 Final Rule. Affected hospitals can expect to receive the reduced payments provided for under the 2019 Final Rule for 340B drugs dispensed at their off-campus outpatient locations unless the court takes similar action in response to the AHA’s additional challenge or CMS voluntarily implements a policy change.
- Although stakeholders also raised concerns about the administrative burdens and expenses associated with the claim modifier requirements implemented under the 2018 Final Rule, there is no indication that CMS is limited in its ability to impose such requirements, nor is it enjoined from doing so under the court’s opinion.
- The court’s opinion suggests that CMS may be unable to significantly reduce reimbursement rates for 340B drugs until it develops specific hospital acquisition cost survey data that demonstrates that the average acquisition costs for 340B drugs is significantly below the ASP plus 6 percent reimbursement rate. It is unclear when, or if, CMS will develop such data. Further, the court’s opinion indicates that it would be difficult for CMS to attempt similar approaches to reduce payments for other specific categories of outpatient drugs for which it believes current Medicare rates do not reflect acquisition costs.
- CMS recently announced its intention to establish an International Pricing Index demonstration project under which the agency would substantially alter how and how much it pays for Part B drugs. In a related OTS, we described potential implications for hospitals participating in and purchasing drugs through the 340B program. If that demonstration is advanced and implemented, it too could affect the outcome and implications of this case.

Top Takeaways for Tax-Exempts from IRS Guidance on Executive Compensation
ARTICLE / CLIENT ALERT
Top Takeaways for Tax-Exempts from IRS Guidance on Executive Compensation
January 3, 2019
Read time: 8 min
One of the more controversial and complex provisions of the Tax Cuts and Jobs Act has been the 21 percent excise tax on certain nonprofit executive compensation. On December 31, 2018, the IRS issued interim guidance that addresses how this tax will apply in various situations that commonly arise for tax-exempt employers. Establishing internal systems to comply with this guidance will be challenging.
One of the more controversial and complex provisions of the Tax Cuts and Jobs Act has been the 21 percent excise tax on certain nonprofit executive compensation. Section 4960 of the Internal Revenue Code imposes this tax on remuneration over $1 million and excess parachute payments that are paid by tax-exempt employers with respect to covered employees for tax years beginning after December 31, 2017. Covered employees for this purpose includes an employee or former employee who is “one of the five highest compensated employees of the organization.”
On December 31, 2018, the IRS issued interim guidance that addresses how this tax will apply in various situations that commonly arise for tax-exempt employers. Overall, the IRS has interpreted Section 4960 in a manner that is unfavorable to tax-exempt employers, particularly nonprofit health systems. Establishing internal systems to determine which employees are covered by this excise tax is likely to be challenging. Key highlights of Notice 2019-09 include:
- Multiple employers within a tax-exempt system can each be separately subject to the excise tax. The phrase “high five employees” is now officially misleading. Each tax-exempt employer must separately determine which of its employees are “covered employees” rather than focusing only on the five highest paid employees across the entire system, as is the case with publicly held corporations subject to Section 162(m). The IRS has rejected the position that a group of related tax-exempt employers should only need to identify its five highest-compensated employees systemwide. This is one of the most controversial provisions of the Notice. As result, complex tax-exempt systems could potentially have several entities with dozens of employees earning compensation that triggers the excise tax.
- Employees earning significantly less than $1 million can be covered employees and covered employee status never ends. There is no minimum dollar threshold for an employee to be a covered employee. Even if a tax-exempt employer has no liability under Section 4960 for one year with respect to a covered employee, it may become subject to an excise tax for that covered employee in a later year. The IRS has confirmed that once an individual is a covered employee by being among the highest five paid employees, he or she retains that status indefinitely even as compensation and services may vary over time. As a result, each tax-exempt employer within a system must identify its covered employees annually and keep a log of covered employees indefinitely.
- The determination of who is a covered employee is complicated. Who is a covered employee with respect to a tax-exempt employer is determined based on remuneration paid by that employer as well as remuneration for services performed as an employee of a related organization. The Notice generally defines a related organization to include any entity, whether or not tax-exempt, using a more-than-50 percent control test. As a result, each tax-exempt employer within a system must determine the extent to which remuneration must be imputed to its employees from related organizations in determining covered employee status. Further complicating matters is that an individual can also be deemed to be an employee of more than one tax-exempt employer. Indeed, it is possible that a single employee could be a covered employee with respect to more than one tax-exempt employer within a system.
- The “medical services” exclusion is very narrowly defined. Section 4960 provides that compensation paid to a licensed medical professional for medical services is not compensation for purposes of determining covered employees or amounts subject to the excise tax. The interim guidance adopts a narrow read and excludes only compensation paid for the “direct performance” of medical services to patients, not compensation for teaching, research, or administration. This interpretation raises logistical challenges for hospitals and health systems. If a Chief Medical Officer’s employment agreement does not expressly allocate the portion of compensation paid for direct medical services versus all other services, the employer must make a reasonable, good faith allocation using billing records (for patients, insurance, Medicare/Medicaid), timesheets, comparable salaries for the non-medical duties performed, or other reasonable bases.
- Multiple entities within a tax-exempt system may be liable for a portion of the excise tax. Determining which entities within a tax-exempt system are liable for the excise tax is also likely to be a complicated exercise. The Notice includes rules for allocating the excise tax among a tax-exempt employer and related organizations. In fact, a tax-exempt employer may have liability under Section 4960 directly for its covered employees and additionally as a related organization, subject to limited relief to avoid double counting compensation payable to the same employee.
- The excise tax can apply to governmental entities. The 21 percent excise tax applies to governmental entities exempt from tax under Section 115 of the Code, as well as other governmental entities that have applied and received recognition of tax-exempt status as Section 501(c)(3) organizations (“dual-qualified” organizations). Only governmental entities that fit neither of these categories can avoid the excise tax (e.g., a state college with no IRS determination letter). For example, if a state university recognized under Section 501(c)(3) pays its covered employee head football coach $5 million per year, it would face an $840,000 excise tax (21 percent of $4 million) during each year of the contract.
- The excise tax is determined based on the calendar year. In order to reduce complexities associated with multi-corporate tax-exempt systems having entities with different tax years, the Notice clarifies that the excise tax is determined on a calendar year basis, not based on the taxable year of the employer. This is an important development for non-fiscal year employers, as it should reduce the administrative burden that might otherwise arise if these employers were required to allocate compensation paid during a single calendar year to multiple fiscal years.
- Compensation vesting in the employer’s taxable year beginning after 2017 (or in any later calendar year) is considered paid when vested. Compensation generally counts toward the $1 million threshold when it vests, rather than when it is paid. Amounts that accrued and vested prior to the employer’s taxable year beginning in 2018 do not count toward the threshold; this is the only grandfathering exception under the Notice.
- Payments made upon separation from service that are less than $1 million can be subject to the excise tax. As noted above, “excess parachute payments” paid to covered employees are subject to the 21 percent excise tax, irrespective of whether those payments are more than $1 million. While based on golden parachute concepts applicable to for-profit companies, the Notice takes an expansive view as to what is an excess parachute payment under Section 4960. Subject to only a few exceptions, most types of compensation triggered by an involuntary separation can potentially be parachute payments, including payments made contingent upon complying with a noncompete and accelerated vesting of benefits even if no actual payment is made. An involuntary separation from service for this purpose generally includes an employee’s termination of employment without cause, an employee’s failure to renew a contract and bona fide good reason employment termination by an employee. There are also special provisions broadly defining separation from service (as compared to Section 409A) to include certain changes to the service relationship, even if an employee is still employed by a tax-exempt employer. As expected, the total payments in the nature of compensation that are contingent upon an involuntary separation from service will only be parachute payments if they are three or more times the employee’s base amount (which is a measure of historic taxable compensation as determined under Section 280G). Excess parachute payments equal the portion of the parachute payments that exceeds the base amount.
- A “good faith, reasonable interpretation” of Section 4960 is sufficient until future guidance is issued. Where open questions remain, tax-exempts must adopt consistent and reasonable approaches to comply with Section 4960 based on all of the facts and circumstances.
The Notice raises many issues for tax-exempt employers. We are continuing to evaluate the Notice and will be sharing additional thoughts going forward to help general counsel and executive compensation committees evaluate the impact of this development.
THINS – Not All They are Crackered Up to Be
ARTICLE
THINS – Not All They are Crackered Up to Be
January 2, 2019
Read time: 2 min
Katherine Tabor authored this bylined article summarizing the US Court of Appeals for the Federal Circuit’s decision to affirm the TTAB’s refusal to register marks for two snack cakes.
Encouraging Experiences of Application for the Italian Lump-Sum Tax Regime
ARTICLE
Encouraging Experiences of Application for the Italian Lump-Sum Tax Regime
November / December 2018
Read time: 2 min
Carlo Maria Paolella and Luca Angelini authored this bylined article outlining the main features of the Italian “lump-sum tax regime,” created in 2017 in order to encourage foreign high-net-worth individuals to move to Italy.

Proposed Foreign Tax Credit Regulations Clarify Taxpayers’ Ability to Claim Deemed Paid Credits
ARTICLE / CLIENT ALERT
Proposed Foreign Tax Credit Regulations Clarify Taxpayers’ Ability to Claim Deemed Paid Credits
December 27, 2018
Read time: 8 min
On November 28, 2018, the Internal Revenue Service (IRS) and the US Department of the Treasury released proposed regulations (REG-105600-18) that address the calculation of a corporate US shareholder’s deemed paid foreign tax credits under section 960. The proposed regulations also make clear that certain foreign income taxes paid by controlled foreign corporations (CFCs) will be “lost,” and the corporate US shareholder can never claim a deemed paid credit with respect to such taxes.
Prior to the 2017 Tax Act, former sections 902 and 960(a)(1) permitted a corporate US shareholder to claim a credit for foreign taxes paid by a CFC when the related income was either distributed to the shareholder as a dividend or included in the shareholder’s income under section 951(a). In both scenarios, the amount of deemed paid foreign taxes was based on multi-year “pools” of earnings and taxes, with the shareholder generally deemed to have paid the same proportion of the CFC’s post-1986 foreign income taxes as the amount of the dividend or subpart F inclusion bore to such CFC’s post-1986 undistributed earnings. In addition, former section 960(a)(3) generally applied the rules of former section 902 in allowing the corporate US shareholder to claim a deemed paid credit for foreign income taxes paid by a CFC on a distribution of previously taxed earnings and profits (PTEP).
The 2017 Tax Act repealed section 902, modified section 960 and generally changed the system for determining the deemed paid credit from multi-year pooling to a “properly attributable” standard. Under new sections 960(a) and (d), a corporate US shareholder can claim a deemed paid credit for foreign income taxes that are properly attributable to current year subpart F income and global intangible low taxed income (GILTI) inclusions, respectively (current year taxes). Current year taxes attributable to GILTI inclusions are further subject to a 20 percent “haircut.” Under new section 960(b), a shareholder is generally deemed to have paid foreign income taxes that are properly attributable to distributions of PTEP received from a first-tier CFC (in the case of a corporate US shareholder) or from a lower-tier CFC (in the case of an upper-tier CFC shareholder) (in both cases, PTEP group taxes). Except for PTEP group taxes, only foreign income taxes paid or accrued by the CFC in a current tax year generally can be deemed paid by a US shareholder.
The proposed regulations provide rules for determining a corporate US shareholder’s deemed paid credits with respect to a CFC’s current year taxes and PTEP group taxes. The determination of deemed paid credits for current year taxes is first made at the lowest-tier CFC and is then repeated for each CFC on a “bottom-up” basis:
- The proposed regulations require CFCs to establish “income groups” within “section 904 categories” to which the CFC’s current year taxes are allocated and apportioned. For CFCs, these section 904 categories generally consist of the general and passive categories, as income of a CFC cannot be assigned to the foreign branch category or the GILTI category.
- Within section 904 categories, the CFC first assigns gross income to subpart F income groups, the tested income group and a residual income group. Subpart F income groups include different groups for each separate item of income under Treas. Reg. § 1.954-1(c)(1)(iii) (e.g., there are separate income groups for foreign base company income and each single item of foreign personal holding company income). Each item of foreign personal holding company income may be assigned to four different groups based on the type of foreign taxes (withholding or not) and the foreign tax rate under Treas. Reg. § 1.904-4(c)(3)(i).
- The CFC then allocates and apportions deductions and current year taxes to income groups and PTEP groups (discussed below) under the principles set forth in corresponding proposed section 904 regulations. If a corporate US shareholder has subpart F income or GILTI inclusions with respect to the CFC’s subpart F income groups or tested income group, deemed paid credits may be available for the shareholder’s proportionate share of current year taxes that have been assigned to the related income group. The deemed paid taxes would be subject to the US shareholder’s section 904 limitation, with the shareholder allocating deemed paid taxes to the separate category to which the related income inclusion is assigned.
- Under the proposed regulations, current year taxes that are allocated to the CFC’s residual income group cannot be deemed paid by the corporate US shareholder. Further, no CFC taxes are deemed paid in connection with section 956 inclusions.
Deemed paid PTEP group taxes are also determined on a “bottom-up” basis, starting with the lowest-tier CFC:
- The proposed regulations require CFCs to establish annual PTEP “accounts” within section 904 categories. Within each account, a CFC must assign PTEP to one of 10 different “PTEP groups” based on the US shareholder’s underlying income inclusion, taking into account any reclassification of PTEP resulting from section 956 inclusions. For example, if a CFC’s tested income is included by a US shareholder under section 951A in 2018, the related earnings would be added to the CFC’s GILTI PTEP group within the 2018 PTEP account in the section 951A category. Notice 2019-01, issued by the IRS and Treasury on December 14, 2018, describes additional regulations that Treasury intends to issue, including regulations that would expand the number of PTEP groups from 10 to 16.
- Distributions from a lower-tier CFC’s PTEP group are added to the upper-tier CFC’s corresponding PTEP group, with current year taxes paid by the upper-tier CFC on the distribution (such as net basis taxes and withholding taxes) assigned to that PTEP group. The PTEP group taxes that are available to be deemed paid by an upper-tier CFC or corporate US shareholder generally consist of the foreign income taxes that have been assigned to the PTEP group (both in the current year and in previous years) from which the PTEP distribution is made.
- Upon receipt of a PTEP distribution, a corporate US shareholder would allocate any deemed paid PTEP group taxes to the same separate category as the annual PTEP account and PTEP group from which the distribution was made, with such taxes subject to the shareholder’s section 904 limitation. The Proposed Regulations do not apply any haircut to withholding taxes paid or deemed paid with respect to distributions of GILTI PTEP.
The proposed regulations do not address the ordering of PTEP distributions. Instead, the preamble notes that the IRS and Treasury anticipate that ordering will be addressed in forthcoming regulations under section 959. Notice 2019-01, as noted above, describes regulations that Treasury intends to issue involving the ordering of PTEP upon distribution and reclassification.
Under the Proposed Regulations, certain foreign income taxes paid by CFCs will be “lost” and unavailable to be credited by corporate US shareholders, including:
- 20 percent of taxes related to GILTI inclusions (i.e., taxes that have been haircut under section 960(d))
- Taxes related to tested income that has been reduced by a tested loss from another CFC
- Taxes related to the “net deemed intangible income return” that reduces the shareholder’s GILTI inclusion
- Taxes related to high-taxed subpart F income that the US shareholder has elected to exclude from subpart F income
- Taxes related to “base differences” (defined in the proposed regulations as taxes imposed on a type of item that does not constitute income under US federal income tax principles, such as gifts or life insurance proceeds)
In addition, the proposed regulations generally allocate taxes attributable to “timing differences” (defined in the proposed regulations as taxes imposed on an item of income that is not recognized for US federal income tax purposes in the current year) to the section 904 category and income group to which the related income would have been allocated if it had been recognized for US federal income tax purposes. If the shareholder does not have subpart F income or GILTI inclusions with respect to such income group in the current year, these taxes would generally be lost, even when the corporate US shareholder recognizes the related income for US tax purposes in a later year. Given the potential for lost taxes, taxpayers should identify any material base differences or timing differences in their CFCs to determine if there will be any related US income inclusions in the current year.
The effective dates in the proposed regulations vary, depending on the provision. The regulations under section 960 are proposed to have “retroactive” effectiveness for taxable years of a foreign corporation beginning after December 31, 2017, and a taxable year of a domestic corporation that is a US shareholder of the foreign corporation in which or with which such taxable year of such foreign corporation ends.
Proposed Foreign Tax Credit Regulations Clarify Taxpayers’ Ability to Claim Deemed Paid Credits
ARTICLE
Proposed Foreign Tax Credit Regulations Clarify Taxpayers’ Ability to Claim Deemed Paid Credits
December 27, 2018
Read time: 2 min
Enrica Ma and Bradford E. LaBonte authored this bylined article outlining the recently released proposed regulations made by the Internal Revenue Service that address the calculation of a corporate US shareholder’s deemed paid foreign tax credits under section 960.
Tax Reform Insights: IRS Proposes Section 163(j) Regulations – New Business Interest Expenses Deduction Limit
ARTICLE
Tax Reform Insights: IRS Proposes Section 163(j) Regulations – New Business Interest Expenses Deduction Limit
December 26, 2018
Read time: 2 min
Kevin Hall, Emily Mussio, Justin Jesse and David Sherwood authored this bylined article about the proposed regulations made by the Internal Revenue Service to limit the amount of business interest a taxpayer may deduct. “With the amendment of Code Section 163(j), the ability of some taxpayers to deduct interest on intercompany debt has been diminished substantially,” they wrote. “This may require a taxpayer to reevaluate funding and capital structures, and may necessitate a new strategy.”